We have just published a MARA Rating for a maintenance treatment in lung cancer.

The trial answered one question clearly: does this treatment extend survival? It does. Patients lived longer than those on the standard treatment.

Reimbursement bodies ask a different question: is the cost per outcome gained within the accepted range?

The answer was no. By a wide margin.

These are not the same question. Clinical development answers the first. Market access depends on the second.

Both questions have clear answers here. They point in opposite directions.

Read the full MARA Rating here: https://mararating.com/report/lurbinectedin-for-in-maintenance-treatment-of-extensive-stage-sclc-after-first-line-induction-without-disease-progression-as-of-may-2026/